Fetal hydantoin syndrome is a rare disorder that is believed to be caused by exposure of a fetus to the anticonvulsant drug phenytoin. The classic features of fetal hydantoin syndrome include craniofacial anomalies, prenatal and postnatal growth deficiencies, underdeveloped nails of the fingers and toes, and mental retardation. Less frequently observed anomalies include cleft lip and palate, microcephaly, ocular defects, cardiovascular anomalies, hypospadias, umbilical and inguinal hernias, and significant developmental delays. Anaesthesia for incidental surgery in such a patient poses unique challenges for the anesthesiologist. We report the successful management of a 4-year-old male child with fetal hydantoin syndrome, cleft palate, spina bifida, atrial septal defect, and dextrocardia for tibialis anterior lengthening under subarachnoid block.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469078 | PMC |
| http://dx.doi.org/10.1155/2012/370412 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bottom-up PBPK modeling of phenytoin brain disposition in postpartum newborns after intrauterine dosing.
Drug Metab Pers Ther
September 2024
Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science & Technology, Irbid, Jordan.
Article Synopsis
- * Researchers used a physiologically based pharmacokinetic (PBPK) model to estimate the levels of phenytoin in newborns, focusing on its concentrations in brain extracellular fluid, plasma, and saliva.
- * Findings indicated that phenytoin levels in the newborns were below harmful thresholds, suggesting that monitoring salivary levels could be a safer method to prevent brain toxicity in infants born to mothers on this medication, though more research is needed on dosing for infants.
Different fetal effects on fingers from exposure to phenytoin, phenobarbital, and carbamazepine.
Am J Med Genet A
September 2024
Hunt Consulting Associates, Chapel Hill, North Carolina, USA.
Exposure at conception to phenytoin (PHT), phenobarbital (PB), and carbamazepine (CBZ) has been associated with several different effects on the fetus, including hypoplasia of the distal phalanges, dysmorphic facial features, and structural abnormalities such as oral clefts and neural tube defects. One question is whether each of these antiepileptic drugs (AEDs) has the same effects or just similar effects. A systematic examination of the fingers of children exposed at conception to PHT, PB, or CBZ, as monotherapy, has been used to address this question.
View Article and Find Full Text PDFFetal Hydantoin Syndrome: A Case Report.
Cureus
November 2023
Neonatology, All India Institute of Medical Sciences, Rishikesh, IND.
Epilepsy is not a common cause of morbidity in pregnancy. It has widespread effects on maternal and fetal health necessitating adequate control of seizures. Many anti-seizure medications (ASM) have teratogenic effects on the fetus.
View Article and Find Full Text PDFExposure to iprodione induces ROS production and mitochondrial dysfunction in porcine trophectoderm and uterine luminal epithelial cells, leading to implantation defects during early pregnancy.
Chemosphere
November 2022
Institute of Animal Molecular Biotechnology and Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, 02841, Republic of Korea. Electronic address:
Iprodione is a well-known fungicide used in the cultivation of strawberries, tomatoes, grapes, and green beans. In recent studies, neurotoxicity, cardiotoxicity, and endocrine toxicity of iprodione have been reported. Although reproductive toxicity of iprodione has been identified in animal studies, its effects are limited to male fertility.
View Article and Find Full Text PDFProteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Int J Cancer
October 2022
Department of Urology, Semmelweis University, Budapest, Hungary.
Enzalutamide (ENZA) is a frequently used therapy in metastatic castration-resistant prostate cancer (mCRPC). Baseline or acquired resistance to ENZA have been observed, but the molecular mechanisms of resistance are poorly understood. We aimed to identify proteins involved in ENZA resistance and to find therapy-predictive serum markers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!